Menlo Park, CA, United States of America

Michael McGuire

USPTO Granted Patents = 3 

Average Co-Inventor Count = 4.5

ph-index = 1


Location History:

  • Harrisonburg, VA (US) (2023)
  • Menlo Park, CA (US) (2024)

Company Filing History:


Years Active: 2023-2025

Loading Chart...
3 patents (USPTO):Explore Patents

Title: Michael McGuire: Innovator in Molecular Guide Systems

Introduction

Michael McGuire is a prominent inventor based in Menlo Park, California. He has made significant contributions to the field of molecular guidance systems, holding a total of 3 patents. His work focuses on innovative methods for targeting intracellular processes, which have important implications for medical treatments.

Latest Patents

One of Michael McGuire's latest patents is centered around molecular guide system peptides and their uses. This patent discloses compositions that comprise an antibody conjugated to one or more molecular guidance system (MGS) peptides. The methods outlined in this patent involve treating subjects in need by administering an effective amount of an antibody that targets an intracellular target involved in the disease process. Additionally, the patent details methods for targeting intracellular targets using these conjugated antibodies.

Career Highlights

Michael McGuire is currently associated with SRI International, where he continues to advance his research and development in molecular guidance systems. His innovative work has positioned him as a key figure in the field, contributing to the understanding and application of antibody conjugation techniques.

Collaborations

Michael collaborates with notable coworkers, including Kathlynn C Brown and Curtis Allred. Their combined expertise enhances the research efforts at SRI International, fostering an environment of innovation and discovery.

Conclusion

Michael McGuire's contributions to molecular guide systems exemplify the impact of innovative thinking in the medical field. His patents and ongoing research continue to pave the way for advancements in targeted therapies.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…